About Moderna Therapeutics
Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.
Missing: Moderna Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Moderna Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Moderna Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Moderna Therapeutics in 7 CB Insights research briefs, most recently on Oct 28, 2022.
Expert Collections containing Moderna Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Moderna Therapeutics is included in 4 Expert Collections, including Synthetic Biology.
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Moderna Therapeutics Patents
Moderna Therapeutics has filed 144 patents.
Molecular biology, RNA, Nucleotides, DNA, Gene expression
Molecular biology, RNA, Nucleotides, DNA, Gene expression
Latest Moderna Therapeutics News
Jan 26, 2023
Drew Angerer/Getty Images News Democratic Sens. Elizabeth Warren (Mass.) and Peter Welch (Vt.) are asking Moderna (NASDAQ: MRNA ) CEO Stephane Bancel to reconsider a price hike for COVID-19 vaccines once they become available through the commercial market. Moderna ( MRNA ), like rival Pfizer ( PFE ), has said it plans to hike the price of its COVID shot to between $110 and $130 per dose, far higher than what the federal government has been paying for them. "Moderna's ( MRNA ) price hikes, aside from threatening public health, also raise questions about how Pfizer's ( PFE ) similar announcement of vaccine price hikes in October 2022 may have influenced Moderna's ( MRNA ) decision-making process regarding its vaccine prices," the senators wrote. The senators also noted that Moderna's ( MRNA ) vaccine was developed through federally funded research. The duo also ask Bancel several questions mostly dealing with revenue and profit expected this year from the vaccine. COVID shots will become available through the commercial market -- rather than for free due to federal government purchases -- after the public health emergency for the virus is declared over.
Moderna Therapeutics Frequently Asked Questions (FAQ)
When was Moderna Therapeutics founded?
Moderna Therapeutics was founded in 2010.
Where is Moderna Therapeutics's headquarters?
Moderna Therapeutics's headquarters is located at 200 Technology Square, Cambridge.
What is Moderna Therapeutics's latest funding round?
Moderna Therapeutics's latest funding round is IPO.
How much did Moderna Therapeutics raise?
Moderna Therapeutics raised a total of $1.961B.
Who are the investors of Moderna Therapeutics?
Investors of Moderna Therapeutics include Merck & Co., Viking Global Investors, Sequoia Capital China, Alexandria Venture Investments, Pictet Group and 18 more.
Who are Moderna Therapeutics's competitors?
Competitors of Moderna Therapeutics include Ethris and 2 more.
Compare Moderna Therapeutics to Competitors
Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.
ReCode Therapeutics is a genetic medicines company for mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. The company's lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.
HDT Bio is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. The company was founded in 2018 and is based in Seattle, Washington.
Ethris develops mRNA therapeutics with a focus on respiratory diseases and vaccines. Its RNA technology platform helps enable the discovery, design, and development of transcript therapies that assist in restoring missing functions in patients' cells and tissues. The company was founded in 2009 and is based in Planegg, Germany.
BioNTech (NASDAQ: BNTX) offers new immunotherapy solutions for cancer and other diseases. The Company focuses on the computational discovery and therapeutic drug platforms for developing biopharmaceuticals. It works with pharmaceutical collaborators, such as Genmab, Sanofi, Genentech, Genevant, Fosun Pharma, and Pfizer. The company was founded in 2008 and is based in Mainz, Germany.
Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.